Last reviewed · How we verify
Valsartan 320 mg
Valsartan 320 mg, marketed by Novartis, is a well-established treatment in the hypertension market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Valsartan 320 mg |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- 24 Hour Ambulatory Cardiac Oxygen Consumption (PHASE3)
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (PHASE1, PHASE2)
- A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension (PHASE3)
- Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril (PHASE3)
- Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension (NA)
- Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan 320 mg CI brief — competitive landscape report
- Valsartan 320 mg updates RSS · CI watch RSS
- Novartis portfolio CI